VEC方案治疗眼内期视网膜母细胞瘤的临床疗效及其安全性评价

Effectiveness and safety of VEC program for intraocular retinoblastoma

目的为提高临床治愈率,探索VEC方案治疗眼内期视网膜母细胞瘤的临床应用价值及其安全性。方法选择2008年1月～2010年12月该院接受治疗的42例眼内期视网膜母细胞瘤患者。回顾分析治疗方案安全性,对照分析不同年龄组VEC方案治疗后效果及缓解组患者治疗前、后肿瘤基底平均直径及肿瘤厚度。结果不同年龄组VEC方案治疗后效果对照显示,缓解者及进展者构成比差异有显著性(P<0.05),无变化者构成比差异无显著性(P>0.05)。缓解组患者治疗前、后肿瘤基底平均直径及肿瘤厚度对照显示,差异有显著性(P<0.05)。所有患者治疗期间均能耐受,无死亡病例出现。结论 VEC方案治疗眼内期视网膜母细胞瘤,对于早期患者,疗效较好,且较为安全。

[ Objective ] For the improvement of clinical cure, to explore the clinical value and safety of VEC treatment for intraocular retinoblastoma. [Methods] 42 patients with intraocular retinoblastoma treated in our department between January 2008 and December 2010 were chosen. The safety of treatments was analyzed retrospectively, and the therapeutic effect of VEC program in different age groups and the basal average diameter and tumor thickness of eased group were comparatively analyzed. [ Results ] The difference of constituent ratios of remissions and deteriorations among different age groups performed VEC was significant （P 〈0.05）, but the difference of constituent ratios of uniformities was not significant （P 〉0.05）. The differences of basal average diameter and tumor thickness of eased group before and after treatment were significant, according to the situation that was controlled （P 〈0.05）. All patients were tolerated during treatment, and no deaths occurred. [Condusion] VEC program has a good curative effect and a high safety for patients with early intraocular retinoblastoma.